Development-stage technology
NEMOW’s lead program is the investigational Uterine Toner Device (UTD), a concept being developed for postpartum hemorrhage associated with uterine atony.
Investors
Supporting the next stage of maternal-health innovation.
NEMOW welcomes professional introductions from prospective strategic investors interested in responsible medical-device development.
Development focusNEMOW UTD is investigational. Its safety and effectiveness require appropriate clinical evaluation.
Investor inquiries
Connect with NEMOW.
NEMOW welcomes introductions and discussions with prospective strategic investors who are interested in maternal-health innovation and medical-device development.
Evidence-first progress
Progress depends on engineering verification, safety evaluation, clinical evidence, regulatory strategy and appropriate partnerships.
Important note
Information for prospective investors
This website is for general corporate information only and is not an offer to sell or a solicitation to buy securities. No investment decision should be based solely on this website. Please contact NEMOW for professional inquiries.